57
Participants
Start Date
May 12, 2016
Primary Completion Date
May 21, 2018
Study Completion Date
August 9, 2018
VIB4920
Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
Placebo
Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
Research Site, Duncansville
Research Site, Jacksonville
Research Site, DeBary
Research Site, Miami Lakes
Research Site, South Miami
Research Site, Anniston
Research Site, Cincinnati
Research Site, Mesquite
Research Site, Bialystok
Research Site, Bydgoszcz
Research Site, Poznan
Research Site, Warsaw
Lead Sponsor
Amgen
INDUSTRY